Nan Ding

Nan Ding

Auto-generated profile, based on publicly available information

Nan Ding

Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
NDNan Ding
Nan Ding
KHKarlijn E.P.E. Hermans
Karlijn E.P.E. Hermans
TNThiemo J.A. van Nijnatten
Thiemo J.A. van Nijnatten
SESanne M.E. Engelen
Sanne M.E. Engelen
JTJolien Tol
Jolien Tol
SGSandra M.E. Geurts
Sandra M.E. Geurts
This study aims to determine whether real-world overall survival (OS) of patients with de Novo HER2-positive (HER2 +) metastatic breast cancer (MBC) in the Netherlands improved over time. Data of patients diagnosed with de Novo HER2 + MBC in 2008-2017 were retrieved from the Netherlands Cancer Registry. OS was estimated per two-year period using the Kaplan-Meier method and compared using the log-rank test for trend and the multivariable Cox proportional hazards analysis, adjusted for baseline characteristics and local therapy. First-given systemic and local therapy use was determined per two-year period. Among 1458 patients included, 99 % (1452/1458) were female and 53 % (775/1458) aged 50-74 years at diagnosis. Comparing patients diagnosed with de Novo HER2 + MBC in 2008-2009 versus 2016-2017, the median OS improved from 30·9 months (95 %CI:25·0-35·4) to 57·3 months (95 %CI:46·7-68·1) (p-value for trend<0·001) (adjusted hazard rate ratio =0·49, 95 %CI:0·40-0·59). The use of any HER2-targeted therapy increased from 64 % (178/279) to 84 % (287/340), while the use of pertuzumab-based therapy increased from 0 % to 67 % (227/340) over the same period. The use of surgery remained stable over time, while radiotherapy use for both the primary tumour and metastases increased in recent years, from 16 % (44/279) and 15 % (42/279) in 2008-2009-22 % (76/340) and 26 % (88/340) in 2016-2017, respectively. OS has doubled over ten years, for patients diagnosed with de Novo HER2 + MBC in the Netherlands between 2008 and 2017. No change in metastatic presentation was observed over time, suggesting the improved OS is most likely explained by treatment improvements.

24 September 2025 in The Breast
Verified
Journal Article
Open access
NDNan Ding
Nan Ding
RVRenee Visserman
Renee Visserman
SGSandra M.E. Geurts
Sandra M.E. Geurts
JTJolien Tol
Jolien Tol
BVBirgit E.P.J. Vriens
Birgit E.P.J. Vriens
MBMaaike de Boer
Maaike de Boer
We aimed to describe real-world complete response (CR) rates, predictors of CR, and survival outcomes in patients treated with first-line pertuzumab, trastuzumab, and chemotherapy for HER2-positive (HER2+) metastatic breast cancer (MBC). Patients with HER2+ MBC who started first-line pertuzumab, trastuzumab, and chemotherapy in 2013-2021 were selected from the SONABRE Registry (NCT-03577197), involving eleven Dutch hospitals. CR was defined as no evidence of disease on imaging during first-line systemic therapy with or without local therapy (surgery and/or radiotherapy). Multivariable logistic regression was used to identify predictors for CR. Progression-free survival (PFS) and overall survival (OS) from the start of first-line pertuzumab, trastuzumab, and chemotherapy were computed with the Kaplan-Meier method. We included 244 patients treated with first-line pertuzumab, trastuzumab, and chemotherapy, with a median follow-up duration of 71 months (interquartile range: 60-82 months). A CR during first-line systemic therapy was reached in 63 patients (26 %). Patients younger than 65 years (odds ratio (OR) = 5.24, 95 %CI:1.49-18.44, p = 0.01), those with de Novo MBC (OR = 2.48, 95 %CI:1.24-4.93, p = 0.01), or those with a single metastatic site (OR = 3.81, 95 %CI:1.83-7.96, p < 0.001) were more likely to reach CR than their counterparts. The 5-year PFS and OS rates were, respectively, 63 % (95 %CI:48 %-75 %) and 85 % (95 %CI:72 %-92 %) in patients with a CR and 10 % (95 %CI:6 %-16 %) and 36 % (95 %CI:28 %-44 %) in patients without a CR. In the real world, one in four patients treated with first-line pertuzumab, trastuzumab, chemotherapy, with or without local therapy, reached CR. Two third of patients with a CR were still free of progression after five years.

24 August 2026 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
NDN. Ding
N. Ding
SGS.M.E. Geurts
S.M.E. Geurts
KHK.E.P.E. Hermans
K.E.P.E. Hermans
IVI.J.H. Vriens
I.J.H. Vriens
RVR. Visserman
R. Visserman
VTV.C.G. Tjan-Heijnen
V.C.G. Tjan-Heijnen

25 July 2026 in The Breast
Verified
Journal Article
Open access
NDNan Ding
Nan Ding
SGSandra M.E. Geurts
Sandra M.E. Geurts
IVIngeborg J.H. Vriens
Ingeborg J.H. Vriens
RVRenée Visserman
Renée Visserman
TNThiemo J.A. van Nijnatten
Thiemo J.A. van Nijnatten
VTVivianne C.G. Tjan-Heijnen
Vivianne C.G. Tjan-Heijnen